MTOR and neoplasm: Examination of dabrafenib-treated BrafV600E/+;Rnf43fl/fl;Znrf3fl/fl lesions revealed a reduction in proliferation, mTOR signalling and tumour growth along with an upregulation of GLUL and a decrease in CDH1 and SOX9 levels (Extended Data Fig. 9o–t).